Trial record 1 of 3 for:    Crinetics
Previous Study | Return to List | Next Study

A Study to Evaluate the Safety and Efficacy of CRN00808 for the Treatment of Acromegaly (ACROBAT EVOLVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03792555
Recruitment Status : Recruiting
First Posted : January 3, 2019
Last Update Posted : January 3, 2019
Information provided by (Responsible Party):
Crinetics Pharmaceuticals Inc.

Brief Summary:
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 (an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.

Condition or disease Intervention/treatment Phase
Acromegaly Drug: CRN00808 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients With Acromegaly That Are Responders to Octreotide LAR or Lanreotide Depot (ACROBAT Evolve)
Actual Study Start Date : December 18, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CRN00808 Drug: CRN00808
CRN00808, capsules, once daily by mouth

Placebo Comparator: Placebo Drug: Placebo
Placebo, capsules, once daily by mouth

Primary Outcome Measures :
  1. Proportion of subjects who meet responder criteria (based on the mean of two consecutive insulin-like growth factor-1 [IGF-1] measurements ≤ upper limit of normal [ULN]) [ Time Frame: 13 Weeks ]

Secondary Outcome Measures :
  1. Proportion of subjects who achieve serum growth hormone (GH) <5.0 ng/mL [ Time Frame: 13 Weeks ]
  2. Change in IGF-1 levels [ Time Frame: From Week 10 to Week 13 ]
  3. Change in GH levels [ Time Frame: From Week 8 to Week 13 ]
  4. Change in symptoms of acromegaly [ Time Frame: From Week 10 to Week 13 ]
    Global assessment of symptoms of acromegaly (headache, excessive sweating, extremity swelling, joint pain, sleep apnea, fatigue, and paresthesia; each assessed consistent with adverse event criteria [mild, moderate, severe])

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects 18 to 70 years of age
  2. Confirmed diagnosis of acromegaly that is controlled on stable doses of octreotide LAR or lanreotide depot
  3. Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, or using effective method(s) of birth control
  4. Willing to provide signed informed consent

Exclusion Criteria:

  1. Treatment naïve acromegaly subjects
  2. Prior treatment with CRN00808
  3. Pituitary surgery within 6 months prior to Screening or radiation therapy at any time prior to the study entry
  4. History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years.
  5. Use of any investigational drug within the past 30 days or 5 half-lives, whichever is longer
  6. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab) or has a history of a positive result
  7. History of alcohol or substance abuse in the past 12 months
  8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study
  9. Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities.
  10. Subjects with symptomatic cholelithiasis
  11. Subjects with clinically significant abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study
  12. Subjects who have been taking the following prior medications: pegvisomant (within the last 3 months), dopamine agonists (within the last 3 months) and pasireotide LAR (within the last 6 months)
  13. Subjects taking octreotide LAR at a dose higher than 40 mg or lanreotide depot at a dose higher than 120 mg
  14. Subjects who usually take octreotide LAR or lanreotide depot less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03792555

Contact: Crinetics Clinical Trials 858-450-6464

United States, Pennsylvania
Allegheny Endocrinology Associates Recruiting
Pittsburgh, Pennsylvania, United States, 15212
University of Pécs Medical School Recruiting
Pécs, Hungary
Sponsors and Collaborators
Crinetics Pharmaceuticals Inc.

Responsible Party: Crinetics Pharmaceuticals Inc. Identifier: NCT03792555     History of Changes
Other Study ID Numbers: CRN00808-02
First Posted: January 3, 2019    Key Record Dates
Last Update Posted: January 3, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Crinetics Pharmaceuticals Inc.:

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases